20 Future Portuguese HealthTech and MedTech Leaders

Nelson Advisors
5 days ago
14 min read

Evolutionary Dynamics of the Portuguese Healthtech Ecosystem: A Comprehensive Analysis of 20 Emerging Leaders and Technological Frontiers

The Portuguese healthtech and medtech landscape has reached a state of systemic maturity, transitioning from a localized cluster of academic spin-offs to a formidable international player in precision medicine, digital surgery, and biotechnology. By the mid-2020s, the national startup ecosystem recorded a 16% increase in active ventures, totalling over 4,700 companies, of which nearly 70% were founded within the preceding five-year window.

This acceleration is not merely numerical but represents a qualitative shift toward high-complexity "Deep Tech" and "Fusion Research," where the barriers between laboratory investigation and clinical implementation are systematically dismantled. The influx of venture capital, reaching €886 million in 2024, a 55% increase over previous years, has provided the necessary liquidity for Portuguese leaders to compete on a global stage, particularly in AI-driven care and sustainable biotechnology.

The Strategic Macro-Environment of Portuguese Life Sciences

The transformation of Portugal into a European health innovation hub is underpinned by several structural factors. First, the decentralisation of innovation beyond Lisbon and Porto has created a "vibrant innovation corridor" encompassing Coimbra and Aveiro supported by academic anchors and regional funding initiatives.

Second, the "Startup Visa" and national funding schemes have established a fertile ground for international talent and capital. Third, the role of institutional "anchors" such as the Champalimaud Foundation and the Institute for Research and Innovation in Health (i3S) has provided the infrastructure for high-risk, high-reward medical breakthroughs.

In this environment, leadership is defined by the ability to navigate the "valley of death" between research and commercialisation. The current vanguard of Portuguese healthtech leaders is characterized by a high degree of technical expertise, often holding advanced PhDs or clinical backgrounds, and a strategic focus on export-driven growth. The following sections analyse 20 of these leaders, categorising their influence by technological domain and institutional impact.

The Vanguard of AI-Driven Care and Digital Infrastructure

The most significant capital injections in the Portuguese healthtech sector have concentrated on Artificial Intelligence (AI) solutions that address clinical labor shortages and diagnostic inefficiencies.

Virgílio Bento: Scaling the AI-First Care Paradigm

Virgílio Bento, the founder and CEO of Sword Health, represents the apex of Portuguese healthtech entrepreneurship. As of early 2026, Sword Health reached a Series Junior post-money valuation of $4.36 billion, positioning it as one of the most valuable private healthtech companies globally. Bento’s strategic vision centers on shifting healthcare from a "human-first" to an "AI-first" model, a transition necessitated by the global shortage of clinical professionals.

Under Bento's leadership, Sword Health has expanded its scope from musculoskeletal (MSK) therapy to comprehensive mental health support with the launch of "Mind" in 2025. This platform utilises a proprietary wearable device, the M-band, to detect early biomarkers of depression and anxiety, enabling proactive outreach by clinicians.

Bento’s execution has successfully attracted major international investors, including General Catalyst and Khosla Ventures, and the company has reportedly saved clients nearly a billion dollars in unnecessary healthcare costs by preventing avoidable surgeries. His stated goal of pursuing an initial public offering (IPO) by 2028 reflects a long-term commitment to rebuilding care delivery through foundational AI research.

Tiago Cunha Costa: Revolutionising Diagnostic Interpretation

Tiago Cunha Costa, founder and CEO of BloodFlow, is addressing a systemic bottleneck in hospital workflows: the interpretation of laboratory results. Founded in 2024 and based in Lisbon, BloodFlow utilises an AI-powered platform for automated blood test interpretation. Costa, a former high-performance swimmer, identified the inefficiency of manual data analysis during his athletic career, where raw data often lacked the clinical context necessary for immediate action.

BloodFlow’s "FlowCore" technology is distinguished by its native integration within Electronic Health Record (EHR) systems using HL7 FHIR standards. This approach ensures data sovereignty, as clinical data is processed entirely on-premise without transferring patient information outside the provider's infrastructure, a critical factor for regulatory compliance and physician trust. In 2025, Costa secured a €1.2 million seed round from 3xP Global, enabling the company to scale its "invisible automation" across European markets.

José Bastos: Defining the Digital Front Door

José Bastos, co-founder and CEO of knok healthcare, has been a central figure in the maturation of Portuguese telemedicine. knok operates a "Digital Front Door" strategy, connecting patients, providers, and healthcare professionals through a seamless digital interface.

Supported by Armilar Venture Partners, Bastos has steered the company toward late-stage VC rounds, focusing on the integration of digital health solutions into the current frameworks of major healthcare providers. His leadership at knok reflects a broader shift toward patient-centric platforms that prioritise accessibility and motivation throughout the recovery journey.

Henrique Martins: Architect of Digital Health Strategy

Professor Henrique Martins, associated with ISCTE-IUL and UBI, is a pivotal leader in the policy and management of digital health in Portugal. As a digital health consultant and a key voice in the Portuguese eHealth Strategy, Martins bridges the gap between technological possibility and regulatory reality.

His work emphasizes the "democratisation of access" and the need for scalable implementation of AI and digital tools in everyday clinical practice. Martins’ influence extends to European policy, where he contributes to discussions on health data hubs and the secondary use of healthcare data.

Leader	Company/Institution	Core Technology	Recent Milestone
Virgílio Bento	Sword Health	AI Physical/Mental Therapy	$4.36B Valuation (Jan 2026)
Tiago Cunha Costa	BloodFlow	AI Diagnostic Analysis	€1.2M Seed Round (July 2025)
José Bastos	knok healthcare	Telemedicine Platform	Late VC Round backing (May 2025)
Henrique Martins	ISCTE-IUL / UBI	Digital Health Strategy	Lead voice in Portuguese eHealth Strategy

Pioneers of the Surgical Metaverse and Advanced Oncology

The Champalimaud Foundation has emerged as a global leader in "Fusion Research," particularly in the development of augmented reality (AR) and digital twin technologies for oncology.

Pedro Gouveia: Architect of the Surgical Metaverse

Dr. Pedro Gouveia, a breast surgeon and researcher at the Champalimaud Clinical Centre, is the primary visionary behind the "MetaBreast" project. Gouveia’s work centres on the "Surgical Metaverse," where AR goggles connected to a health data cloud allow surgeons to superimpose 3D digital twins of tumors directly onto a patient's body in the operating room.This non-invasive, image-guided precision surgery aims to ensure clear surgical margins and reduce the need for repeat operations.

Supported by approximately €1.4 million in funding from the Portuguese Resilience and Recovery Plan (PRR), Gouveia has established a Digital Surgery Lab that combines AI, computer vision, and immersive visualization. His leadership is characterised by a focus on "technological literacy" and the removal of cognitive burdens for surgeons, facilitating better-informed decision-making at scale.

Markus Büchler: Transforming Pancreatic Cancer Care

Professor Markus W. Büchler, an internationally renowned pancreatic surgeon with a record of over 3,000 surgeries, was appointed Director of the Botton-Champalimaud Pancreatic Cancer Centre in April 2023. Büchler’s arrival in Lisbon signifies Portugal’s ability to attract top-tier global talent to lead multidisciplinary teams of surgeons, scientists, and computational biologists.

The Centre, funded by a €50 million partnership with the Mauricio and Charlotte Botton couple, is the first in the world to simultaneously integrate research and treatment for pancreatic cancer. Under Büchler’s direction, the Centre utilises a BSL-2-compliant cGMP Gene Therapy Facility to produce CAR-T cells for clinical trials, embodying a translational methodology that brings innovations swiftly into clinical practice.

Tiago Marques and João Santinha: Leading Deep Learning in Radiology

Within the Marques-Santinha Lab at the Champalimaud Foundation, Tiago Marques and João Santinha lead the development of AI algorithms designed to enhance the accuracy of screening and diagnosis. Their research leverages deep learning to segment fat and fibroglandular tissue in MRIs, which is essential for creating the precise 3D digital twins used in Gouveia's surgical metaverse.

By focusing on the "generalisability and robustness" of AI models, Marques and Santinha are accelerating the clinical adoption of these tools across diverse healthcare settings.

Albino Oliveira-Maia: Integrating AI into Neuropsychiatry

As the Director of the Neuropsychiatry Unit at the Champalimaud Foundation, Albino Oliveira-Maia is at the forefront of applying AI to mental health diagnostics. His work involves exploring how digital neuro-therapeutics and AI virtual assistants can revolutionise medical practice and research in neuropsychiatry.

Oliveira-Maia’s leadership is critical in bridging the foundation's strengths in neuroscience with the emerging capabilities of generative AI and medical imaging.

Leaders in Biotechnology and Sustainable Nutrition

The Portuguese biotech sector is experiencing a renaissance in "Blue Biotechnology" and precision fermentation, addressing global challenges in nutrition and resource sustainability.

Ali Osman: Driving Precision Fermentation for Human Health

Ali Osman, founder and CEO of PFX Biotech, is a central figure in the development of human milk proteins via precision fermentation. Based in Porto and incubated at UPTEC, PFX Biotech uses engineering biology to produce functional ingredients such as lactoferrin, which is associated with immune system support and iron regulation.

In mid-2025, Osman secured a total of €5 million in funding, including a €2.5 million seed round led by Buenavista Equity Partners and a matching €2.5 million grant from the EIC Accelerator. Osman’s team combines deep operational know-how with scientific depth, aiming to make precision fermentation commercially viable at scale. PFX Biotech’s proteins provide a safer, allergen-free alternative for infant formulas and advanced nutrition for the elderly and athletes.

9. Vítor Verdelho: Pioneering Cellular Aquaculture

Vítor Verdelho, CEO of Cell4Food, is leading the first Portuguese company dedicated to cellular aquaculture. A spin-off from the University of Porto, Cell4Food is developing technologies to produce cell-based seafood, beginning with octopus cells (Octopus vulgaris). Verdelho’s strategy centers on a B2B model, creating and licensing technological platforms for the agri-food industry to support more sustainable and resilient food systems.

In early 2026, Cell4Food secured €1.5 million to advance its cell-based seafood innovation, utilizing AI-powered bioprocess modeling to reduce trial-and-error experimentation by 80%. Verdelho’s vision positions Portugal as a relevant player in the European blue transition, dissociating food production from the direct exploitation of marine resources.

Bruno Sarmento: Advancing Nanomedicine and Drug Delivery

Professor Bruno Sarmento, a researcher at i3S and co-founder of the spin-off Inovapotek, is a global leader in controlled drug delivery systems. In 2026, Sarmento will assume the presidency of the Controlled Release Society, the largest international scientific society in the field.

His research focuses on the development of functionalised nanomedicines for diabetes, cancer, and infectious diseases, as well as three-dimensional tissue engineering models for the in vitro validation of these medicines. Sarmento’s leadership at i3S and his involvement in global pharmaceutical nanotechnologies highlight Porto's role as a major hub for translational drug delivery research.

Innovators in Immunotherapy and the Fight Against AMR

The challenge of Antimicrobial Resistance (AMR) has spurred the development of novel immunotherapies by leaders who are redefining how we treat infectious diseases.

Bruno Santos and Pedro Madureira: Neutralising Bacterial Virulence

Bruno Santos (CEO) and Pedro Madureira (CSO) are the co-founders of Immunethep, a biotechnology company that originated as a spin-off from the University of Porto. Immunethep’s innovation is based on Madureira’s discovery of a virulence mechanism shared by life-threatening bacteria, such as E. coli and K. pneumoniae. The bacteria release a protein variant called bGAPDH, which shifts the host’s immune response toward an anti-inflammatory state, making the body more susceptible to infection.

Under their leadership, Immunethep has developed the "Paragon Novel Vaccine" (PNV), the first in the world to simultaneously prevent infections from five critical bacteria. In 2025, the company received $2 million from CARB-X and additional funding from PACE to advance its monoclonal antibody program. Santos’s background in biological engineering and MBA training complements Madureira’s scientific discoveries, moving Immunethep toward human clinical trials and international partnerships with top pharma companies.

Leader	Company	Focus Area	Impact Metric
Ali Osman	PFX Biotech	Precision Fermentation	€5M Seed/Grant (2025)
Vítor Verdelho	Cell4Food	Cellular Aquaculture	€1.5M Portugal 2030 (2026)
Bruno Santos	Immunethep	AMR Immunotherapy	$2M CARB-X Funding (2025)
Bruno Sarmento	i3S / Inovapotek	Nanomedicine	President-Elect Controlled Release Society

Leaders in Medtech and Bioengineered Materials

Materials science and bioengineering in Portugal are producing leaders who are developing autonomous, battery-free medical devices and advanced diagnostic tools.

12 Andreia T. Pereira: Pioneering Batteryless Medical Devices

Andreia T. Pereira, a junior researcher at i3S, is at the vanguard of "BioTribo," a research line focusing on energy-harvesting systems for biomedical use. Her work involves using the human body as an inexhaustible energy source to power smart medical devices, such as pacemakers, through triboelectric nanogenerators.

Pereira’s research also includes developing graphene-based composites for blood-contacting devices that prevent thrombosis and bacterial adhesion. Her contributions have been recognized with the Maria de Sousa Prize and the L'Oréal Portugal Honor Medal for Women in Science.

Alexandre Barros: Advancing Biodegradable Medtech

Alexandre Barros, the CEO and Business Development Manager at Hydrumedical (Hydrustent SA), has led the commercialisation of biodegradable urological stents. Hydrumedical's patented technology allows for the creation of the first 100% biodegradable ureteral stent, which avoids the need for a second surgery and reduces treatment costs by 60%.

Under Barros’s leadership, the company has expanded into stoma care and infection control lines, achieving international certifications (ISO 13485) and establishing a certified production site in Guimarães.

Ricardo Moura: Scaling Anthropometric Ecosystems

Ricardo Moura, co-founder and CEO of Wisify Tech Solutions, has built a measurement ecosystem trusted by sports nutritionists and performance teams globally. Wisify’s products, Lipowise and Gripwise, are digital devices for evaluating body composition and muscle strength, connecting hardware and software to monitor frailty and sarcopenia.

Moura’s leadership has focused on creating a complete clinical workflow that makes precision measurement accessible and actionable for professionals in five markets.

Diana S. Nascimento: Innovating Cardiovascular Regeneration

Diana S. Nascimento, an investigator at i3S and professor at ICBAS, is a leader in bioengineered therapies for cardiovascular disorders. Her research focuses on heart repair using piezoelectric materials to drive cardiac regeneration and inhibit fibrosis.

Nascimento’s work bridges fundamental and applied research, addressing the formation of fibrosis and the aging of the extracellular matrix after injury, contributing significantly to the field of regenerative medicine in Portugal.

Strategists in Digital Health and Professional Efficiency

The broader digital health ecosystem in Portugal is shaped by leaders focused on clinical efficiency, professional networking, and long-term ecosystem development.

Joana Pinto: Gamifying Physiotherapy

Joana Pinto, co-founder and CEO of Clynx, is redefining physiotherapy delivery through gamification. A participant in the 2018 EIT Health InnoStars Awards, Clynx improves the patient experience by supporting flexible, motivating care. Pinto has been recognised as one of Europe's most influential women in the startup space, highlighting the potential of gamified digital health tools to ease pressure on healthcare systems.

José Paulo Carvalho: Scaling Remote Patient Monitoring

José Paulo Carvalho, founder and board member of Hopecare, is a pioneer in remote patient monitoring in Portugal. His work focuses on integrating digital health into current clinical frameworks, helping patients manage chronic conditions from home. Carvalho’s role as an executive board member at TICE.PT highlights his influence in the Portuguese information and communication technology cluster for health.

Cláudio Costa: Leading Clinical Research and Intelligence

Cláudio Costa, CEO and founder of ActOne Intelligence & Research, is a key figure in the application of intelligence and data analytics to clinical research. ActOne focuses on providing deep insights that drive decisions in the life sciences sector, reflecting the growing importance of analytics in the Portuguese healthtech landscape.

David Magboulé: Facilitating Technology Transfer

David Siqueira Magboulé, CEO at LabtoMarket, is a leader in bridging the gap between academic research and commercial applications. LabtoMarket works with researchers and institutions to identify market-ready technologies and facilitate their transition into the healthcare ecosystem. His leadership is essential for the continuous flow of innovation from Portugal's strong academic base to the global market.

Filipa Fixe: Steering Corporate Health Innovation

Filipa Fixe, as an executive leader at Glintt Global, oversees one of the largest technology and consulting groups in the Iberian Peninsula focused on healthcare. Her work involves managing digital health solutions for hospitals and pharmacies, ensuring that large-scale clinical institutions can adopt and integrate the innovations coming from the startup ecosystem. Fixe’s role is critical for the "robustness and transparency" of healthcare processes at the corporate level.

Technical Foundations: A Comparative Analysis of Medtech Innovations

The leadership demonstrated by these 20 individuals is deeply rooted in the technical superiority and unique mechanisms of their respective technologies. The following table provides a comparative overview of the core technological drivers for selected leaders.

Leader	Primary Platform	Technical Mechanism	Strategic Implication
Pedro Gouveia	MetaBreast / AR	3D-Digital Twin Superposition	Precision surgery; zero repeat procedures
Tiago C. Costa	FlowCore / AI	HL7 FHIR Native EHR Processing	Data sovereignty; zero external data transfer
Pedro Madureira	Immunethep / PNV	bGAPDH Neutralization	Anti-bacterial therapy without AMR risk
Andreia T. Pereira	BioTribo / Nanogen	Triboelectric Energy Harvesting	Battery-free, autonomous implants
Vítor Verdelho	Cell4Food	Cellular Blue Biotechnology	Sustainable seafood; resource dissociation
Virgílio Bento	Sword AI	Multi-modal Deep Learning	Unlocking $MSK$ and mental health access

Institutional Synergy and the "Fusion Research" Model

The emergence of these leaders is not an isolated phenomenon but the result of a deliberate "Fusion Research" model adopted by Portuguese institutions. The Champalimaud Foundation and i3S exemplify this by housing surgical services, research labs, and clinical trials under one roof.

The Champalimaud Centre for the Unknown: A Catalyst for Metaverse Surgery

The architecture and mission of the Champalimaud Centre for the Unknown (CCU) are designed to "bridge the gap between laboratory and clinic". This environment allows leaders like Gouveia and Büchler to test digital surgery solutions in "Immersive Surgical Arenas" that mimic real operating rooms.

The creation of a health data cloud infrastructure by CCU scientists ensures that medical data can be transferred and stored securely, virtually via the internet, which is a prerequisite for the commercialisation of medical devices in the surgical metaverse.

i3S: A Porto-Based Hub for Bioengineering

Similarly, the Institute for Research and Innovation in Health (i3S) in Porto merges three founding institutes (IBMC, INEB, and IPATIMUP) to face aging, infectious diseases, and regenerative medicine. This integrative nature provides leaders like Bruno Sarmento and Andreia Pereira with access to state-of-the-art facilities and a multidisciplinary team of clinicians and researchers.

The "Nanomedicines & Translational Drug Delivery" group at i3S, led by Sarmento, is a testament to how institutional solidity fosters international leadership in complex fields like pharmaceutical nanotechnology.

The Investment Landscape: 2025 and Beyond

The funding trajectory for Portuguese healthtech in 2025-2026 indicates a shift toward "Endurance and Adoption". While previous years focused on rapid digitisation, the current phase prioritises "sustainable technology" and "clinical validation".

The Role of Portugal Ventures and 3xP Global

Portugal Ventures, the national venture capital company, remains a foundational supporter, managing a portfolio of 20+ life sciences companies and offering pre-seed funding through initiatives like "Call INNOV-ID". The appointment of new leadership for the 2025-2027 triennium focuses on making the institution a "closer and more agile partner" for health and biotechnology startups.

Concurrently, private equity firms like 3xP Global are launching dedicated "Health Innovation Funds". Their investment in BloodFlow highlights a focus on "infrastructure-level solutions" that turn routine diagnostics into real-time decisions.This strategic alignment between institutional support and focused private capital is

essential for the global expansion of Portuguese healthtech leaders.

Ecosystem Maturation: Regional Hubs and Decentralization

The decentralisation of the startup scene is a hallmark of Portugal's maturing ecosystem. While Lisbon and Porto are the primary centres, the growth of cities like Coimbra and Aveiro signals a national trend where innovation is no longer confined to the capital.

The Porto-Coimbra-Lisbon Corridor

The "Porto Region" saw a significant increase in investment volume in 2025, driven by a mix of early-stage activity and scale-up rounds for companies like PFX Biotech and Immunethep. The Biocant Park in Cantanhede (near Coimbra) has provided the ideal conditions for Immunethep to expand its R&D facilities independently.

This regional specialisation, Porto for bioengineering and drug delivery, Lisbon for digital surgery and AI, and the Coimbra region for immunotherapy and vaccines—creates a diversified and resilient national healthtech portfolio.

Future Outlook: Indicators of Sustained Leadership

As we look toward 2027, the success of these 20 leaders will be measured by their ability to achieve several key benchmarks:

Clinical Adoption at Scale: Transitioning from research projects (e.g., MetaBreast) to widely implemented medical devices in everyday clinical practice.
Regulatory Clearance (CE-marked and FDA-cleared): Achieving medical device certification is a critical goal for leaders like Tiago Costa (BloodFlow) to become the "invisible standard layer" of diagnostics worldwide.
Global Commercial Readiness: For biotech leaders like Ali Osman (PFX Biotech), accelerating the path to commercial launch for allergen-free human milk proteins is the next "defining moment"
Successful IPOs and Record Exits: Virgílio Bento’s target of an IPO by 2028 will serve as a bellwether for the entire Portuguese healthtech sector, signalling its ability to produce global health leaders at scale.

The Portuguese healthtech and medtech ecosystem is no longer in its infancy. It is characterized by leaders who combine scientific depth with entrepreneurial drive, supported by institutions that prioritize translational impact.

The integration of AI, augmented reality and precision biotechnology into the clinical landscape is not just a future possibility, it is a transformation currently being enacted by these 20 leaders. As visibility and reliability outperform novelty, the Lusitanian life sciences sector is positioned for long-term endurance on the global stage.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech